ISRG Stock: Intuitive Surgical BEAT Q2 2026 — So Why Did It Crash 12%? (Cheap at Last, or Value Trap?)

Intuitive Surgical (ISRG) Q2 2026 — Intuitive Surgical (ISRG) reported a clean Q2 2026 beat: revenue $2.89B (+19% YoY), non-GAAP EPS $2.80 (beat $2.48, +28%), GAAP EPS $2.29; worldwide procedures +16% (da Vinci +15%, Ion +36%); 468 da Vinci systems placed (246 were da Vinci 5) vs 395 a year ago; installed base 11,710 (+12%). Instruments & accessories $1.73B (+18%, ~60% of revenue); non-GAAP gross margin 70.0%; operating margin >40%; $8.63B cash and zero debt; $0.38B buyback. Yet the stock FELL ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high — because FY26 da Vinci procedure-growth guidance of 13.5-15.5% marked a clear step down from the high-teens, alongside softer hospital surgery volumes and a da Vinci Class II component recall. Our owner-earnings DCF lands ~$343, essentially on top of the ~$352 price. Wall Street: Buy (39 of 56), avg target ~$525. Our call: HOLD, 3/5 — a premier compounder now at roughly fair value; not a bargain yet. Intuitive Surgical is the pioneer and monopoly of robotic-assisted surgery — the da Vinci system, the Ion lung-biopsy robot, and a razor-and-blade model where over 76% of revenue recurs. In Q2 2026 it delivered a clean beat: revenue $2.89B (+19%), non-GAAP EPS $2.80 (vs $2.48), worldwide procedures +16%, non-GAAP gross margin 70%, and 468 da Vinci placements (246 da Vinci 5), lifting the installed base 12% to 11,710. And yet the stock fell ~12.6% to a fresh 52-week low near $352 — down ~42% from its $604 high. The reason isn't the quarter; it's the guide: FY26 da Vinci procedure growth of 13.5-15.5% (management points to the midpoint) is a step down from the high-teens pace of recent years, compounded by softer hospital volumes and a Class II recall. For a stock still near 33x forward earnings, decelerating procedure growth is the number that matters most. Our owner-earnings DCF (base ~$3.2B/yr, +$8.6B net cash) spans $246-$463 across 8-10% discount rates and 10-14% growth, with a probability-weighted value near $343 — roughly on top of today's ~$352. Wall Street rates it a Buy with a ~$525 target (nearly 50% upside), but even our bullish path only reaches the mid-$400s, and on the Street's own EPS estimates the math lands near our $343. Our call: HOLD, 3/5 — a wide-moat monopoly that has finally de-rated to fair value, but is not yet a bargain. Own the quality; look to add below $300; watch the quarterly procedure line above all else. Not financial advice. THE CALL: HOLD (3/5, A PREMIER SURGICAL-ROBOTICS MONOPOLY — NOW ROUGHLY FAIR, WAIT FOR A BETTER PRICE) — base-case value ~$343 vs ~$352 today. What to watch: da Vinci procedure growth stabilizing and re-accelerating back toward the high-teens (da Vinci 5 lifting procedures per system), which would justify the premium multiple — or, conversely, a pullback below ~$300 that opens a genuine margin of safety and turns us to a buy; the thesis breaks if procedure growth slides below 12% or tariff/competition pressures compress margins Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.